Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $251.5501, but opened at $232.50. Genmab A/S shares last traded at $232.50, with a volume of 254 shares.
Genmab A/S Trading Up 0.1%
The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The company has a market cap of $14.32 billion, a PE ratio of 17.53 and a beta of 0.81. The business’s 50-day simple moving average is $267.58 and its 200-day simple moving average is $296.74.
About Genmab A/S
Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.
Further Reading
- Five stocks we like better than Genmab A/S
- Motorola’s $1.5B Bet to Own the Skies
- AI’s Power Crunch Is Putting Uranium Energy Back on Investors’ Watchlists
- What IBM’s $10-Billion Quantum Project Means For Smaller Players
- HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
